Bank Pictet & Cie Europe AG Sells 6,591 Shares of Moderna, Inc. $MRNA

Bank Pictet & Cie Europe AG trimmed its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 47.3% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 7,356 shares of the company’s stock after selling 6,591 shares during the quarter. Bank Pictet & Cie Europe AG’s holdings in Moderna were worth $1,417,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Kercheville Advisors LLC purchased a new position in shares of Moderna in the 3rd quarter worth approximately $260,000. Abel Hall LLC purchased a new stake in Moderna during the third quarter valued at approximately $399,000. OceanIQ Capital LLC purchased a new stake in Moderna during the third quarter valued at approximately $385,000. SteelPeak Wealth LLC lifted its position in Moderna by 3.9% during the third quarter. SteelPeak Wealth LLC now owns 3,397 shares of the company’s stock valued at $654,000 after acquiring an additional 127 shares during the last quarter. Finally, Western Pacific Wealth Management LP acquired a new stake in Moderna in the third quarter valued at approximately $29,000. 75.33% of the stock is currently owned by institutional investors.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Investor attention is centered on detailed Phase 3 melanoma data for Moderna’s personalized cancer therapy, expected Saturday. The potential readout is viewed as a major catalyst for the company’s oncology strategy and helped support recent buying interest. What’s Going On With Moderna Stock Monday?
• Positive Sentiment: Oddo BHF raised its Moderna price target to $251 from $170, signaling substantially improved expectations for the company’s pipeline and commercial outlook. Oddo BHF Adjusts Moderna Price Target
• Positive Sentiment: Moderna’s collaboration with Merck is among the oncology programs expected to draw attention at ESMO 2026, keeping investors focused on clinical progress and the potential value of its cancer-vaccine platform. Merck/Moderna and Others to Headline ESMO 2026
• Positive Sentiment: Moderna is being highlighted alongside other healthcare companies benefiting from AI-driven drug development, testing and sequencing trends. This provides additional growth-oriented investor interest, although it is more thematic than tied to near-term financial results. The AI Trade Just Moved Into Your Bloodstream
• Neutral Sentiment: Moderna remains listed among biotech stocks for investors to watch, reflecting continued market interest but not a specific new company catalyst. Top Biotech Stocks to Add to Your Watchlist
• Neutral Sentiment: Coverage of investment-firm views on MRNA indicates ongoing institutional debate over the stock’s valuation, pipeline prospects and risk profile, without a clearly stated new consensus shift. What Are Investment Firms Thinking About Moderna?
• Negative Sentiment: Moderna President Stephen Hoge reported selling shares under a predetermined trading plan. The transaction may be routine, but insider selling can weigh on sentiment, particularly after the stock’s strong run. Stephen Hoge Sells Shares Under Trading Plan
• Negative Sentiment: Separate reports said Moderna’s president sold approximately $8.4 million and $8.6 million of stock. The apparent overlap may represent related reporting of insider transactions, but the sales could reinforce concerns about valuation and executive confidence. Moderna President Sells Stock Insider Selling at Moderna
• Negative Sentiment: A bearish Seeking Alpha analysis argues that investors may be overestimating Moderna’s cancer-vaccine opportunity, highlighting execution, clinical and commercialization risks ahead of definitive data. Moderna: Sell the Cancer Vaccine Hype

Insiders Place Their Bets

In other Moderna news, insider Shannon Klinger sold 3,471 shares of the firm’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total value of $485,766.45. Following the completion of the transaction, the insider owned 74,129 shares of the company’s stock, valued at approximately $10,374,353.55. This trade represents a 4.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 40,294 shares of Moderna stock in a transaction on Monday, September 14th. The stock was sold at an average price of $144.13, for a total transaction of $5,807,574.22. Following the sale, the president owned 1,525,858 shares of the company’s stock, valued at $219,921,913.54. The trade was a 2.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 197,251 shares of company stock valued at $33,875,904. Insiders own 10.80% of the company’s stock.

Moderna Stock Performance

Shares of Moderna stock traded up $13.07 during midday trading on Tuesday, hitting $239.96. The company had a trading volume of 8,637,973 shares, compared to its average volume of 12,354,278. The stock has a market cap of $95.80 billion, a price-to-earnings ratio of -29.93 and a beta of 1.09. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. The company has a fifty day simple moving average of $160.00 and a 200 day simple moving average of $92.42. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $242.29.

Moderna (NASDAQ:MRNA) last released its earnings results on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, topping the consensus estimate of ($2.03) by $0.06. The company had revenue of $145.00 million for the quarter, compared to the consensus estimate of $102.93 million. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. Moderna’s revenue was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($2.13) EPS. As a group, analysts predict that Moderna, Inc. will post -6.11 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Bank of America lifted their price target on shares of Moderna from $170.00 to $200.00 and gave the stock a “neutral” rating in a report on Friday, October 9th. Brookline Capital Markets reiterated a “buy” rating on shares of Moderna in a report on Wednesday, August 19th. Bradesco Corretora upgraded Moderna to an “outperform” rating in a report on Friday, August 28th. Jefferies Financial Group reissued a “hold” rating and issued a $150.00 price objective (up from $60.00) on shares of Moderna in a research report on Wednesday, August 19th. Finally, JPMorgan Chase & Co. boosted their target price on Moderna from $40.00 to $77.00 and gave the stock an “underweight” rating in a research note on Friday, August 21st. Seven analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and four have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $101.45.

Moderna Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.